Edoxaban versus warfarin in patients with atrial fibrillation
Journal
The New England journal of medicine
Journal Volume
369
Journal Issue
22
Pages
2093
Date Issued
2013-11-28
Author(s)
Giugliano, Robert P
Ruff, Christian T
Braunwald, Eugene
Murphy, Sabina A
Wiviott, Stephen D
Halperin, Jonathan L
Waldo, Albert L
Ezekowitz, Michael D
Weitz, Jeffrey I
Špinar, Jindřich
Ruzyllo, Witold
Ruda, Mikhail
Koretsune, Yukihiro
Betcher, Joshua
Shi, Minggao
Grip, Laura T
Patel, Shirali P
Patel, Indravadan
Hanyok, James J
Mercuri, Michele
Antman, Elliott M
Abstract
Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.
Subjects
FACTOR XA INHIBITOR; ORAL ANTICOAGULANTS; STROKE; PHARMACOKINETICS; METAANALYSIS; GENERATION; PREVENTION; SAFETY
Publisher
MASSACHUSETTS MEDICAL SOC
Type
journal article